RxDoctor Payments Data

Ahmed Saeed, MD

Gastroenterology · Kansas City, MONPI 1033423744

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (31.1%), education and consulting fees — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Olympus Corporation Of The Americas at 34.2% of the total. Among gastroenterology clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$245,888in general payments, 2019–2025

Across 590 payments — averaging $416.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Olympus Corporation Of The Americas$84K
  • Boston Scientific$55K
  • Olympus America Inc.$42K
  • Endogastric Solutions, Inc$25K
  • Medtronic$22K
  • Merit Medical Systems Inc$6K
  • plus $12K from 24 others

What the payments were for

  • Consulting fees$57,82624%
  • Speaking & faculty fees$76,39631%
  • Travel & lodging$28,56612%
  • Food & beverage$13,3245%
  • Education$69,77628%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$245,888 in reported general payments places this provider in the 95th percentile of 374 gastroenterology providers in Missouri.

See all gastroenterology providers in Missouri

Medicare billing

Part B allowed, 2024
$189,686
Medicare patients
636
Services billed
1,386

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MotegrityPrucalopride Succinate12$6,409
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates53$3,399
SutabSod Sulf/Pot Chloride/Mag Sulf18$2,924
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl51$761
Pantoprazole Sodium44$558
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl23$353

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$271$6,40912 claims
Braintree Laboratories, Inc.Sutab$30$2,92418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 374 gastroenterology providers in Missouri.

Other gastroenterology in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →